Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + toripalimab + paclitaxel + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a multi-agent combination regimen consisting of five drugs: anlotinib (a small molecule multi-targeted tyrosine kinase inhibitor), toripalimab (a monoclonal antibody immune checkpoint inhibitor targeting PD-1), paclitaxel (a microtubule-stabilizing chemotherapeutic agent), cisplatin, and carboplatin (both platinum-based chemotherapeutics). This combination is being investigated as a first-line treatment for advanced cancers, including cervical cancer and potentially other solid tumors. The rationale for this regimen is to combine antiangiogenic therapy (anlotinib) with immunotherapy (toripalimab) and cytotoxic chemotherapy to maximize antitumor efficacy through complementary mechanisms: inhibition of tumor angiogenesis, enhancement of antitumor immune response, and direct cytotoxicity against rapidly dividing tumor cells[2][3].
- Other names
- toripalimab-Ruijin Hospital-cervical cancerToripalimab and Anlotinib with Chemo for Advanced Cervical Cancer
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)MET (Mesenchymal-epithelial transition factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TUBB (Tubulin (alpha and beta subunits))DNAVEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on anlotinib + toripalimab + paclitaxel + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + toripalimab + paclitaxel + cisplatin + carboplatin.